Hepatitis C: A retrospective study, literature review, and naturopathic protocol

Alternative Medicine Review

Volumn 5, Issue 4, 2000, Pages 355-370

  Milliman, W B ^a   Lamson, D W ^a   Brignall, M S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASCORBIC ACID; COD LIVER OIL; COLCHICINE; CYANOCOBALAMIN; FOLIC ACID; GLYCYRRHIZA EXTRACT; INTERFERON; LIV 52; MELATONIN; PRASTERONE; SELENIUM; SILYMARIN; THIOCTIC ACID; THYMUS EXTRACT; URSODEOXYCHOLIC ACID; XIAO CHAI HU TANG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIFESTYLE; LIVER BIOPSY; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ALANINE TRANSAMINASE; COMPLEMENTARY THERAPIES; DIET; HEPATITIS C; HUMANS; LIFE STYLE; NATUROPATHY; PHYTOTHERAPY; RETROSPECTIVE STUDIES;

EID: 0033838796     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Hepatitis C: An update on the silent epidemic
2. 45-Year follow-up of hepatitis C virus infection in healthy young adults
3. Pathogenesis, natural history, treatment, prevention of hepatitis C
4. Treatment of patients with chronic hepatitis C and normal ALT levels
5. Natural history of hepatitis C virus carries with persistently normal aminotransferase levels
6. Exploring the role of diet in modifying the effect of known disease determinants: Application to risk factors of liver cirrhosis
7. Beneficial effect of salmon roe phosphatidylcholine in chronic liver disease
8. The effect of human tumor necrosis factor alpha interleukin 1-beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil
9. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies
10. Effects of branched-chain amino acid-enriched nutrient mixture on natural killer cell activity in viral cirrhosis
11. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy
12. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
13. Relationship between iron concentration and hepatitis C virus RNA level in liver tissue
14. Nutrient intake and iron status of Australian male vegetarians
15. Nonheme-iron absorption, fecal ferritin excretion, and blood indexes of iron status in women consuming controlled lactoovovegetarian diets for 8 wk
16. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis
17. Hepatitis C and alcohol
18. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan
19. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease
20. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
21. Are HCV-infected individuals candidates for hepatitis A vaccine?
22. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
23. Diabetes mellitus: A predictor of cirrhosis in chronic viral hepatitis
24. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection
25. Effect of colchicine on collagen albumin and transferrin synthesis by cirrhotic rat liver slices
26. Treatment with colchicine, survival of patients with ascitic cirrhosis: A double-blind randomized trial
27. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis
28. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid
29. Colchicine in chronic hepatitis B: A pilot study
30. Cytoprotection with ursodeoxycholic acid: Effect in chronic non-cholestatic and chronic cholestatic liver disease
31. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: Influence of HCV genotypes and severity of liver disease
32. Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial
33. Effect of ursodeoxycholic acid on autoim-mune-associated chronic hepatitis C
34. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: A multicenter placebo-controlled study
35. Cytoprotection in the nineties: Experience with ursodeoxycholic acid and silymarin in chronic liver disease
36. Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: Preliminary results
37. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB 1016) in chronic active hepatitis
38. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multi-center trial
39. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
40. Milk thistle (Silybum marianum) for the therapy of liver disease
41. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in mice
42. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9)
43. A multicenter randomized controlled clinical trial of Sho-saiko-to in chronic active hepatitis
44. An autopsy case of interstitial pneumonia probably induced by Sho-saiko-to
45. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis
46. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features
47. Oxidative DNA damage in circulating leukocytes occurs as early event in chronic HCV infection
48. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C
49. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: A randomized, double-blind, placebo-controlled study
50. Interferon/antioxidant combination therapy for chronic hepatitis C - A controlled pilot trial
51. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin
52. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection
53. Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates
54. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: Correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns
55. N-Acetyl cysteine enhances the response to interferonalpha in chronic hepatitis C: A pilot study
56. Time course of total cysteine, glutathione, homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine
57. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, selenium: Three case histories
58. Alpha-lipoic acid in liver metabolism and disease
59. A pilot study of thymus extract in chronic non-A, non-B hepatitis
60. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon
61. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: Preliminary results
62. A pilot study of thymosin alpha 1 therapy in chronic active hepatitis C
63. In vivo modulating effect of a calf thymus acid lysate on human T lymphocyte subsets and CD4+/CD8+ ration in the course of different diseases
64. The long term efficacy of glycyrrhizin in chronic hepatitis C patients
65. Effects of high dose therapy with Stronger Neo-Minophagen C on hepatic histography in non-A, non-B chronic active hepatitis
66. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled trial
67. Glycyrrhizic acid inhibits virus growth and inactivates virus particles
68. Gastrointestinal absorption characteristics of glycyrrhizin from glycyrrhiza extract
69. Phase I pharmacology and toxicity study of glycyrrhetinic acid as a chemopreventive drug
70. Licorice-induced pseudoaldosteronism
71. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication
72. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus
73. Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus
74. TNF-alpha in chronic hepatitis C: The smoking gun?
75. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection
76. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity
77. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection
78. Mechanistic findings of green tea as cancer preventive for humans
79. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances
80. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases
81. The effects of two new antagonists of secretory PLA2 on TNF, iNOS, COX-2 expression in activated macrophages
82. Quercetin inhibits LPS-induced nitric oxide tumor necrosis factor-alpha production in murine macrophages
83. Down regulation of tumour necrosis factor activity in experimental hepatitis by a herbal formulation, Liv 52
84. Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment
85. Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: Independent effect from secondary weight reduction in genetically obese Zucker fatty rats
86. Melatonin as biological response modifier in cancer patients
87. Interferon, cortisone, and antivirals in the treatment of chronic viral hepatitis: A review of 30 years of therapy
88. DHEA and DHEA-S: A review
89. Is there a role for melatonin in the treatment of neoplastic cachexia?
90. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: A study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin
91. The treatment of viral hepatitis
92. Vitamin B12 deficiency: A new risk factor for breast cancer
93. Folate: Effects on carcinogenesis and the potential for cancer chemoprevention
94. Management of hepatitis C